Accepted Manuscript Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ ribavirin: a phase III randomized controlled trial Jan Sperl, Gabor Horvath, Waldemar Halota, Juan Arenas Ruiz-Tapiador, Anca Streinu-Cercel, Ligita Jancoriene, Klara Werling, Hege Kileng, Seyfettin Koklu, Jan Gerstoft, Petr Urbanek, Robert Flisiak, Rafael Leiva, Edita Kazenaite, Renate Prinzing, Sushma Patel MS, Jingjun Qiu, Ernest Asante-Appiah, Janice Wahl, Bach-Yen Nguyen, Eliav Barr, Heather L. Platt PII: S0168-8278(16)30429-9 DOI: http://dx.doi.org/10.1016/j.jhep.2016.07.050 Reference: JHEPAT 6235 To appear in: Journal of Hepatology Received Date: 7 June 2016 Revised Date: 27 July 2016 Accepted Date: 30 July 2016 Please cite this article as: Sperl, J., Horvath, G., Halota, W., Ruiz-Tapiador, J.A., Streinu-Cercel, A., Jancoriene, L., Werling, K., Kileng, H., Koklu, S., Gerstoft, J., Urbanek, P., Flisiak, R., Leiva, R., Kazenaite, E., Prinzing, R., MS, S.P., Qiu, J., Asante-Appiah, E., Wahl, J., Nguyen, B-Y., Barr, E., Platt, H.L., Efficacy and safety of elbasvir/ grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial, Journal of Hepatology (2016), doi: http://dx.doi.org/10.1016/j.jhep.2016.07.050 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.